Physician profile

Alan D Brook

Pulmonary Disease · Saint Peters, MO

NPI 1316938863

$15,734.75

in general payments reported to CMS, 2019-2025

48 companies · $3,400 in 2025

The $3,400 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,279.74
Education$82.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $3,050.55 2019-2025 Trelegy Ellipta, Nucala, Arexvy
Astrazeneca Pharmaceuticals Lp $3,050.39 2019-2025 Breztri, Fasenra, Airsupra
Boehringer Ingelheim Pharmaceuticals, INC. $846.69 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Grifols USA, LLC $799.36 2019-2025 Prolastin-C Liquid
Regeneron Healthcare Solutions, INC. $551.77 2019-2025 Dupixent
Genzyme Corporation $543.69 2019-2025
Novartis Pharmaceuticals Corporation $540.55 2019-2024
Actelion Pharmaceuticals US, INC. $524.70 2019-2023 Uptravi, Opsumit
Stryker Corporation $457.70 2021-2025 Evolve Proline, Broadway 8
Jazz Pharmaceuticals INC. $453.71 2019-2024
Insmed, INC. $449.39 2019-2025 Arikayce, Brinsupri
Mylan Specialty L.P. $371.77 2019-2024 Yupelri
Harmony Biosciences LLC $361.22 2024-2025
Philips North America LLC $330.29 2019-2025 Encore, Vest Therapy Und, (8874) Incourage
United Therapeutics Corporation $324.95 2019-2024 Tyvaso
Show all 48 companies
CompanyGeneral paymentsYearsTop products
Electromed, INC. $322.41 2019-2025 Smartvest
Genentech USA, INC. $312.15 2019-2025 Xolair
Merck Sharp & Dohme LLC $284.74 2021-2025 Zerbaxa, Recarbrio, Winrevair
Takeda Pharmaceuticals U.S.A., INC. $271.71 2020-2025 Glassia
Pfizer INC. $202.94 2019-2025
Amgen INC. $191.63 2022-2024 Tezspire
Imperative Care, INC $176.77 2025 Zoom 88-T Large Distal Platform
Medtronic, INC. $174.99 2025
Bayer Healthcare Pharmaceuticals INC. $154.24 2019-2022
Axsome Therapeutics, INC. $139.91 2023-2025 Sunosi
Sunovion Pharmaceuticals INC. $123.33 2019-2020
Boston Scientific Corporation $101.92 2024 Intracept
Verona Pharma, INC. $66.51 2025 Ohtuvayre
Teva Pharmaceuticals USA, INC. $54.90 2019-2021
Avadel Cns Pharmaceuticals, LLC $53.81 2024-2025 Lumryz
Abbvie INC. $43.62 2023-2024 Teflaro
Resmed Corp $42.94 2021-2023
Apria Healthcare LLC $33.77 2021
Janssen Pharmaceuticals, INC $32.23 2019-2021
Shionogi INC $31.78 2022
Azurity Pharmaceuticals, INC. $31.16 2025 Alvesco
Pulmonx Corporation $29.81 2021-2022
Tactile Systems Technology INC $23.38 2022
Sanofi-Aventis U.S. LLC $23.16 2020
Lilly USA, LLC $21.49 2025 Zepbound
Baxter Healthcare $20.81 2025 Hillrom - Vest System Model 105 Home Care
Veran Medical Technologies, INC. $18.47 2021
Shire North American Group INC $17.93 2019
Phadia US INC. $16.68 2023 Immunocap
E.R. Squibb & Sons, L.L.C. $16.55 2024 Eliquis
Vifor Pharma, INC. $15.02 2024 Veltassa
Advanced Respiratory, INC $14.62 2019
Gilead Sciences, INC. $12.64 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Alan D Brook

$15,734.75

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $3,400 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/105113/alan-d-brook

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.